tetano
Editor, Senior Moderator
Genes Cells
. 2022 Nov 19.
doi: 10.1111/gtc.12992. Online ahead of print.
Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model
Satoru Morimoto[SUP] #[/SUP][SUP] 1 [/SUP], Koichi Saeki[SUP] #[/SUP][SUP] 2 [/SUP], Masaru Takeshita[SUP] 3 [/SUP], Kunio Hirano[SUP] 2 [/SUP], Mariko Shirakawa[SUP] 2 [/SUP], Yumiko Yamada[SUP] 2 [/SUP], Shiho Nakamura[SUP] 1 [/SUP], Fumiko Ozawa[SUP] 1 [/SUP], Hideyuki Okano[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) epidemic remains worldwide. The usefulness of the intranasal vaccine and boost immunization against severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) has recently received much attention. We developed an intranasal SARS-CoV-2 vaccine by loading the receptor binding domain of the S protein (S-RBD) of SARS-CoV-2 as an antigen into an F-deficient Sendai virus vector. After the S-RBD-Fd antigen with trimer formation ability was intranasally administered to mice, S-RBD-specific IgM, IgG, IgA, and neutralizing antibody titers were increased in serum or bronchoalveolar lavage fluid for 12 weeks. Furthermore, in mice that received a booster dose at week 8, a marked increase in neutralizing antibodies in the serum and bronchoalveolar lavage fluid was observed at the final evaluation at week 12, which neutralized the pseudotyped lentivirus expressing the SARS-CoV-2 spike protein, indicating the usefulness of the Sendai virus-based SARS-CoV-2 intranasal vaccine. This article is protected by copyright. All rights reserved.
Keywords: SARS-CoV-2; Sendai virus; intranasal vaccine; neutralizing antibodies.
. 2022 Nov 19.
doi: 10.1111/gtc.12992. Online ahead of print.
Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model
Satoru Morimoto[SUP] #[/SUP][SUP] 1 [/SUP], Koichi Saeki[SUP] #[/SUP][SUP] 2 [/SUP], Masaru Takeshita[SUP] 3 [/SUP], Kunio Hirano[SUP] 2 [/SUP], Mariko Shirakawa[SUP] 2 [/SUP], Yumiko Yamada[SUP] 2 [/SUP], Shiho Nakamura[SUP] 1 [/SUP], Fumiko Ozawa[SUP] 1 [/SUP], Hideyuki Okano[SUP] 1 [/SUP]
Affiliations
- PMID: 36401755
- DOI: 10.1111/gtc.12992
Abstract
The coronavirus disease 2019 (COVID-19) epidemic remains worldwide. The usefulness of the intranasal vaccine and boost immunization against severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) has recently received much attention. We developed an intranasal SARS-CoV-2 vaccine by loading the receptor binding domain of the S protein (S-RBD) of SARS-CoV-2 as an antigen into an F-deficient Sendai virus vector. After the S-RBD-Fd antigen with trimer formation ability was intranasally administered to mice, S-RBD-specific IgM, IgG, IgA, and neutralizing antibody titers were increased in serum or bronchoalveolar lavage fluid for 12 weeks. Furthermore, in mice that received a booster dose at week 8, a marked increase in neutralizing antibodies in the serum and bronchoalveolar lavage fluid was observed at the final evaluation at week 12, which neutralized the pseudotyped lentivirus expressing the SARS-CoV-2 spike protein, indicating the usefulness of the Sendai virus-based SARS-CoV-2 intranasal vaccine. This article is protected by copyright. All rights reserved.
Keywords: SARS-CoV-2; Sendai virus; intranasal vaccine; neutralizing antibodies.